Theratechnologies Inc. (THTX) announced promising preliminary results concerning the tolerability and efficacy of sudocetaxel zendusortide in its ongoing Phase 1b trial for patients with advanced ovarian cancer.
The research enrolled 13 participants and was separated into two groups, Arms A and B, with a structured treatment regimen of three weeks on therapy followed by one week off, on a 28-day cycle.
Participants in Arm A were administered a dose of 1.75 mg/kg/week of sudocetaxel zendusortide. In contrast, those in Arm B received a higher dose of 2.5 mg/kg/week through a weekly infusion.
The trial's findings revealed a lack of dose-limiting toxicities in both groups, marking a positive step for the treatment's safety profile.
In Arm A, there were no significant responses noted among the five patients. However, in Arm B, three out of six patients exhibited considerable reductions in the CA-125 ovarian tumor marker and experienced tumor shrinkage. Remarkably, one patient achieved a complete resolution of a liver lesion.
Based on these results, the Medical Review Committee has unanimously endorsed the continued evaluation and the investigation of higher doses of sudocetaxel zendusortide.
Currently, shares of Theratechnologies are trading at $1.49 on Nasdaq, reflecting an increase of 4.93%.
